(E)-N-[(2R,3R,4R,5R,6R)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-N-[(2R,3R,4R,5R,6R)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide
• 化学式: C₃₀H₄₆N₄O₁₆
• 分子量: 718.7
• InChiKey: ZHSGGJXRNHWHRS-PEALBESXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.1
• 重原子数：
  50
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  306
• 氢给体数：
  11
• 氢受体数：
  16

文献信息

• METHODS FOR PROMOTING MYELINATION, NEURONAL SURVIVAL AND OLIGODENDROCYTE DIFFERENTIATION VIA ADMINISTRATION OF SP35 OR TRKA ANTAGONISTS
  申请人：Biogen Idec MA Inc.

  公开号：EP2068866A2

  公开（公告）日：2009-06-17
• MITTEL ZUR VORBEUGUNG UND BEHANDLUNG DER PITYRIASIS VERSICOLOR
  申请人：Justus-Liebig-Universität Gießen

  公开号：EP2387396B1

  公开（公告）日：2017-11-15
• USE OF COMPOUNDS FOR THE TREATMENT OF PAIN
  申请人：Akron Molecules AG

  公开号：EP2846788A1

  公开（公告）日：2015-03-18
• Methods for Promoting Myelination, Neuronal Survival and Oligodendrocyte Differentiation Via Administration of SP35 or TrkA Antagonists
  申请人：Mi Sha

  公开号：US20100074907A1

  公开（公告）日：2010-03-25

  This invention relates to methods for promoting myelination, neuronal survival, and oligodendrocyte differentiation and treating demyelination and dysmyelination disease by the administration of a TrkA antagonist. The invention also relates to methods of inhibiting or decreasing Sp35 expression by the use of a TrkA antagonist. Additionally, the invention relates generally to methods for blocking Sp35 and TrkA interaction and inhibiting or decreasing TrkA phosphorylation by the administration of a Sp35 antagonist.
• Agent For Preventing And Treating Pityriasis Versicolor
  申请人：Mayser Peter

  公开号：US20120129800A1

  公开（公告）日：2012-05-24

  The present invention concerns an agent for prevention and treatment of pityriasis. The agent according to the present invention comprises at least one transaminase inhibitor effectively inhibiting the transamination process which is of pathogenetic relevance for the disease, prevents a recurrence of the disease and which protects the human skin flora. Upon release into the environment, no resistances are induced in other fungi.